• About Olokizumab
  • Clinical trials
  • Safety of olokizumab
  • What Is rheumatoid arthritis?
  • Prescribing information and instruction
  • Olokizumab SupportPlus and Resources
  • About Olokizumab
  • Clinical trials
  • Safety of olokizumab
  • What Is rheumatoid arthritis?
  • Prescribing information and instruction
  • Olokizumab SupportPlus and Resources
  • Pharmacological properties
  • Mechanism of action
  • Indications for use and contraindications
  • Clinical efficacy
  • International clinical trials Credo
  • Профиль безопасности
  • Побочные эффекты
  • Key factors about rheumatoid arthritis
  • Memo for a specialist
Contact us
Potential violations of the law, the code of business ethics, anti-corruption or anti-monopoly policies, as well as the conflict of interest provisions can be reported anonymously to the hotline
Legal address of the company: Russian Federation 123154, Moscow, Berzarina St., 19, bldg. 1. Please note that by sending information to the e-mail address safety@rpharm.ru, you give your consent to the processing of your personal data by JSC R-Pharm. We guarantee that any personal data received will be processed exclusively in accordance with the policy of JSC R-Pharm regarding the processing of personal data. You can revoke your consent to the processing of personal data at any time by sending a statement about this to JSC R-Pharm or by e-mail safety@rpharm.ru
To report adverse events associated with the use of medicinal products manufactured by JSC R-Pharm, complaints about product quality, and to obtain medical and scientific information about the company’s products.
+7 495 232 41 67
whistleblower@rpharm.ru
artlegia@rpharm.ru
Answer to any question about the olokizumab
safety@rpharm.ru
  • About olokizumab
  • Clinical trials
  • Safety information
  • What Is rheumatoid arthritis?
  • Instructions to use
  • Helpful literature
  • Olokizumab SupportPlus and Resources
PROMO-160824002